Skip to main content
. 2025 Jul 30;104(8):4175–4187. doi: 10.1007/s00277-025-06498-5

Table 3.

Description of AEs (grade 3/4) leading to treatment changes by SOC classes and Preferred Terms (PT) per SOC in patients of set #1 (n=188)

Grade 3/4 AE leading to
Any change* Dose reduction Interruption Discontinuation
n % n % n % n %
Patients with AE of any SOC 18 9.6 3 1.6 7 3.7 11 5.9
Blood and lymphatic system disorders 4 2.1 1 0.5 3 1.6 1 0.5
   Neutropenia 3 1.6 - - 3 1.6 1 0.5
   Haematotoxicity 1 0.5 1 0.5 - - - -
Infections and infestations 4 2.1 - - 1 0.5 3 1.6
   Coronavirus infection 2 1.1 - - 1 0.5 1 0.5
   Brain abscess 1 0.5 - - - - 1 0.5
   Septic shock 1 0.5 - - - - 1 0.5
Cardiac disorders 2 1.1 - - - - 2 1.1
   Angina pectoris 1 0.5 - - - - 1 0.5
   Myocardial infarction 1 0.5 - - - - 1 0.5
Eye disorders 1 0.5 - - 1 0.5 1 0.5
   Diplopia 1 0.5 - - 1 0.5 1 0.5
Gastrointestinal disorders 1 0.5 - - - - 1 0.5
   Diarrhoea 1 0.5 - - - - 1 0.5
General disorders and administration site conditions 1 0.5 - - - - 1 0.5
   General physical health deterioration 1 0.5 - - - - 1 0.5
Injury, poisoning and procedural complications 1 0.5 - - 1 0.5 - -
   Post procedural haematoma 1 0.5 - - 1 0.5 - -
Metabolism and nutrition disorders 1 0.5 1 0.5 - - - -
   Hyponatraemia 1 0.5 1 0.5 - - - -
Neoplasms benign, malignant and unspecified 1 0.5 - - - - 1 0.5
   Lung adenocarcinoma 1 0.5 - - - - 1 0.5
Respiratory, thoracic and mediastinal disorders 1 0.5 - - - - 1 0.5
   Acute respiratory failure 1 0.5 - - - - 1 0.5
Not specified** 2 1.1 1 0.5 1 0.5 1 0.5

*Any change includes change or interruption or discontinuation - one AE can lead to different changes

**No more information at the time of the interim analysis - SOC: System Organ Class according to MedDRA V25.0